Results 1 to 10 of about 684,564 (144)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.

PLoS ONE, 2020
Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells.
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Erina Minato, Atsushi Kobayashi, Ryo Ando, Nobuya Sasaki, Daisuke Miyakoshi, Osamu Ichii, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +14 more
doaj   +4 more sources

PD-L1: expression regulation

Blood Science, 2023
Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their ...
Yu-Jie Zhou, Guoli Li, Jiyin Wang, Mengyuan Liu, Zihan Wang, Yu Song, Xulong Zhang, Xi Wang   +7 more
doaj   +3 more sources

Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy

Cancer Management and Research, 2017
Lingdong Shao,* Qingqin Peng,* Kaixin Du,* Junyan He, Yaping Dong, Xiaoyi Lin, Jinluan Li, Junxin Wu Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China *These ...
Shao LD, Peng QQ, Du KX, He JY, Dong YP, Lin XY, Li JL, Wu JX   +7 more
doaj   +1 more source

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition

Frontiers in Oncology, 2022
The two most common antibody targeting principles in oncology are the induction of direct antitumor effects and the release of antitumor T cell immunity by immune checkpoint blockade. These two principles, however, may be overlapping if the targeted checkpoint molecule is not located on the immune cell but on the tumor cell itself. Secondary resistance
Luise Victoria Claaß, Christoph Schultheiß, Rebekka Scholz, Lisa Paschold, Donjete Simnica, Volker Heinemann, Sebastian Stintzing, Mascha Binder   +7 more
openaire   +3 more sources

PD-L1 [PDF]

Journal of Clinical Pathology, 2017
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive ...
Kythreotou A., Siddique A., Mauri F. A., Bower M., Pinato D. J.   +4 more
openaire   +3 more sources

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1

Frontiers in Oncology, 2022
The breakthrough in the discovery of immune checkpoint PD-1/PD-L1 inhibitors, such as the series of Bristol Myers Squibb synthetic compounds, boosted the research of small molecules with blockade effects on the interaction of PD-1/PD-L1.
Huifang Li, Navindra P. Seeram, Chang Liu, Hang Ma   +3 more
doaj   +1 more source

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma [PDF]

Journal of Thoracic Disease, 2020
Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained.
Yokoyama, Shintaro, Miyoshi, Hiroaki
openaire   +2 more sources

Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration

Frontiers in Cell and Developmental Biology, 2021
Programmed cell death ligand 1 (PD-L1) is widely expressed in a variety of human tumors, and inhibition of the PD-L1/PD-1 pathway represents one of the most promising therapy for many types of cancer.
Ruirui Wang, Fujing Huang, Wei Wei, Yu Zhou, Zi Ye, Liya Yu, Junyuan Hu, Cheguo Cai, Cheguo Cai   +8 more
doaj   +1 more source

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

Frontiers in Immunology, 2020
PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment. However, low response rates suggest that patient selection based on PD-L1 protein expression is not optimal.
Jossie Rotman, Jossie Rotman, Leontine A. S. den Otter, Maaike C. G. Bleeker, Sanne S. Samuels, A. Marijne Heeren, Margaretha G. M. Roemer, Gemma G. Kenter, Gemma G. Kenter, Henry J. M. A. A. Zijlmans, Nienke E. van Trommel, Tanja D. de Gruijl, Ekaterina S. Jordanova, Ekaterina S. Jordanova   +13 more
doaj   +1 more source

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

Biology, 2021
Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma (UC). Therefore, this study evaluated the relationship between PD-L1 expression in circulating tumor cells (CTCs) and treatment response ...
Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai, Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao, Chien-Chang Kao, Chin-Li Chen, Guang-Huan Sun, Dah-Shyong Yu, Sun-Yran Chang, Ming-Hsin Yang   +13 more
doaj   +1 more source